Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 111 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication augmentation Clear all
Withdrawn Phase 2 Interventional

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

NCT03290963
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction

NCT03039036
View directory record Official record
Conditions
Labor Induction
Interventions
Amniotomy, Foley Catheter, Misoprostol
Procedure · Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parent Emotion Coaching for Anorexia Nervosa

NCT04421989
View directory record Official record
Conditions
Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions
Emotion Coaching, Support Group
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 20, 2026, 5:39 PM EDT
Withdrawn Phase 4 Interventional

Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

NCT04192110
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diuretic initiation or augmentation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 4 Interventional

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

NCT05535920
View directory record Official record
Conditions
Hyperkalemia
Interventions
LOKELMA 5 GM Powder for Oral Suspension
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence

NCT01874951
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

NCT00672932
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2013 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Abilify as an Adjunctive Treatment for Refractory Depression

NCT00220636
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aripiprazole
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 20, 2026, 5:39 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
View directory record Official record
Conditions
Motion Sickness, Space, Motion Simulation, Parabolic Flight
Interventions
DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of PN40082 for Lip Augmentation

NCT04032977
View directory record Official record
Conditions
Lip Augmentation
Interventions
PN40082, Restylane Silk
Device
Lead sponsor
Prollenium Medical Technologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

NCT05268094
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Ductal Arterial Stent, Systemic-to-Pulmonary Artery Shunt
Device · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
1 Day to 30 Days
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Augmentation of Fear Response in Humans

NCT01665573
View directory record Official record
Conditions
Fear Conditioning
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX

NCT02517671
View directory record Official record
Conditions
Cardiovascular Disease, Pulmonary Disease
Interventions
Enhanced External Counterpulsation (EECP)
Device
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 20, 2026, 5:39 PM EDT
Not listed Early Phase 1 Interventional

Augmentation of Cognitive Training in Children With TBI With D-Cyloserine

NCT02312635
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
D-Cycloserine, Cogmed Working Memory Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

NCT01206608
View directory record Official record
Conditions
Postoperative Pain
Interventions
SKY0402 + bupivacaine HCl, Mid-dose SKY0402 + bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Effect of Omega-3 Fatty Acid on Cortical Function in ADHD

NCT01883817
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers

NCT02973425
View directory record Official record
Conditions
Smoking Cessation
Interventions
Take a Break as an augmentation to NRT-sampling in Motivation Phase, NRT and mHealth assessment tool without feedback
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Worcester, Massachusetts • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

NCT02922725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine, Placebo control
Drug · Other
Lead sponsor
Brent Michael Kious, MD, PhD
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

NCT01669421
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 Antitrypsin (human)
Drug
Lead sponsor
Michael Campos, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

NCT06404099
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 5:39 PM EDT